Status:
COMPLETED
Assessment of the Antiviral Effect of Atorvastatin on Hepatitis C Virus
Lead Sponsor:
Massachusetts General Hospital
Conditions:
Hepatitis C
Eligibility:
All Genders
30-80 years
Phase:
PHASE2
Brief Summary
We hypothesize that atorvastatin will decrease HCV viral load in patients taking the medication. Cholesterol is needed for HCV virion production. Cell culture studies have shown that atorvastatin (an...
Detailed Description
Men and women ages 30 to 80 infected with HCV viremia whose physician has determined need cholesterol lowering medication will be recruited by the study investigators from Massachusetts General Hospit...
Eligibility Criteria
Inclusion
- Patients with chronic HCV.
- Patients who need treatment for their elevated cholesterol:
- Total cholesterol \>240 or
- LDL \>160 without cardiac risk factors or
- LDL \>130 with two cardiac risk factors (hypertension, smoker, family history of heart attach, or HDL \<40 for men or \<50 for women) or
- LDL \>100 with diabetes or known coronary artery disease
Exclusion
- Impaired mental ability preventing a subject from understanding the protocol or from completing the entire study.
- HCC
- A history of an adverse reaction to any HMG CoA reductase inhibitor.
- Patients who are on HCV treatment, who plan to initiate HCV treatment within 3 months, or who discontinued HCV treatment within the last 3 months.
- Patients whose aminotransferases are \> 5 times the upper limit of normal.
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
End Date :
July 1 2006
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00403533
Start Date
February 1 2006
End Date
July 1 2006
Last Update
November 23 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114